Griffett Selected to Serve with NIH Center for Scientific Review Early Career Reviewer Program
Published on 23 October 2020
Kristine Griffett, Ph.D., assistant professor of pharmacology at University of Health Sciences and Pharmacy in St. Louis, has been chosen to serve with the National Institutes of Health (NIH) Center for Scientific Review’s Early Career Reviewer (ECR) Program.
In her new role with the ECR program, Griffett is responsible for reviewing grant proposals as part of the NIH Center for Scientific Review Drug Discovery for the Nervous System Study Section (DDNS), which is focused on the review of grant applications related to the central nervous system on topics such as anxiety, depression, addiction, analgesia and Alzheimer’s disease.
As the sole ECR reviewer in the DDNS Study Section, Griffett represents one of just a handful of individuals chosen to review grant applications as part of the ECR Program, which aims to help early career scientists become more competitive as grant applicants through firsthand experience with peer review.
“The ECR Program is a very selective and prestigious program, which I had personally spent nearly two years applying to get into,” Griffett said. “I was thrilled to have been chosen as an Early Career Reviewer, and even more excited to learn that I would have the chance to sit on an NIH Study Section. As an early-stage investigator, this service represents a great opportunity for me to further develop my own grant writing skills while also learning more about how to review, critique and score grant proposals developed by other investigators.”
The ECR Program is open to individuals with at least two years of experience as full-time faculty members or researchers who can demonstrate evidence of participation in an active, independent research program. ECR applicants must also have published at least one senior-authored research publication in a peer-reviewed journal in the last two years and have authored at least one additional senior-authored research publication since receiving their doctorate.
As an assistant professor of pharmacology at the University and a member of the research team at the Center for Clinical Pharmacology, Griffett studies nuclear receptors to develop targeted therapeutics for cardio-metabolic diseases, including diabetes, Alzheimer’s disease, obesity, atherosclerosis and fatty liver disease. Through her focus on nuclear receptors, Griffett’s work looks at the underlying causes of disease and examines how many diseases can share a single underlying cause.
“What excites me most about being selected for the ECR Program and my service on the DDNS Study Section is the opportunity to talk to people who are true experts in their field about the science behind the grant proposals that we’re reviewing,” Griffett said. “The DDNS Study Section features individuals from industry, academia and even those with startup companies. This exposure to a wide variety of researchers and their breadth of knowledge allows me to see firsthand how people in my field are thinking about research projects and how they attack research questions.”
Griffett notes that her involvement with the ECR Program also offers new opportunities for collaborations.
“This service gets my name out there as a new investigator and exposes my fellow research colleagues to the topics I’m interested in,” Griffett explained. “This is a really exciting opportunity because it has the ability to open so many doors to new research partnerships.”